UBX News and Press, Unity Biotechnology Inc. From 11/16/23

2023-11-16 13:09:59 ET More on Unity Biotechnology Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16 UNITY Biotechnology to exercise warrants for $4.38M in gross proceeds Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data...

2023-11-16 08:32:33 ET WaveDancer  ( WAVD ) +108% Announces Merger Agreement with Firefly Neuroscience. HNR Acquisition  ( HNRA ) +19% Announces Completion of its Business Combination by Acquisition of Pogo Resources, LLC; HNRA begins Managing and Operating...

Unity Biotechnology Inc. (UBX) is expected to report $-0.87 for Q3 2023

2023-11-14 01:01:35 ET More on Unity Biotechnology UNITY Biotechnology to exercise warrants for $4.38M in gross proceeds Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unit...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023. ȁ...

2023-11-10 13:20:36 ET More on Unity Biotechnology Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unity Biotechnology For further details see: UNITY Biotechnology to ex...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive a...

Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monother...

2023-08-08 17:28:31 ET Unity Biotechnology press release ( NASDAQ: UBX ): Q2 GAAP EPS of -$0.85 in-line. Cash, cash equivalents and marketable securities totaled $71.0 million as of June 30, 2023 compared with $94.8 million as of December 31, 2022. UNITY believes that ...

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We...